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doi:10.1016/j.jmii.2012.03.006Background/Purpose: The aim of the study was to describe the clinical features of children
affected by juvenile idiopathic arthritis (JIA) under the International League of Associations
for Rheumatology-derived classification criteria in a community-based setting.
Methods: Consecutive cases of JIA from defined geographic areas of Taiwan were diagnosed and
followed in an observational cohort from 1995 to 2010. In addition to the clinical and laboratory
data required for the International League of Associations for Rheumatology system, informa-
tion about the medication and disease activity during the study period was also recorded.
Results: Out of 292 children with chronic joint pain, 195 were diagnosed as JIA: systemic
arthritis (19%), oligoarthritis (persistent 16.4%; extended 6.7%), polyarthritis rheumatoid
factor-negative (11.8%), polyarthritis rheumatoid factor-positive (4.6%), psoriatic arthritis
(1.5%), enthesitis-related arthritis (ERA; 37.4%), and undifferentiated arthritis (2.6%). Human
leukocyte antigen-B27 was positive in 82.2% of patients with ERA. Uveitis was observed in
6.7% of patients. Disease-modifying anti-rheumatic drugs, including biologic medications, were
used in 73.3% of children during the observational period. At the last follow-up, 40% of patients
experienced a continuously active or relapsing course.
Conclusion: Compared with previous reports on Western populations, a remarkably high preva-
lence was found in the ERA of the Chinese cohort, but a relatively low rate of uveitis. OngoingAllergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital,
Taiwan.
rg.tw (J.-L. Huang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Clinical features of JIA in Taiwan 289disease activity was evident in a substantial number of children. These results provided a good
starting point in understanding the epidemiology of this serious disease in the Chinese population.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Juvenile idiopathic arthritis (JIA) is not a single disease and
comprisesdas an “umbrella” termdall chronic arthritides
of unknown etiology persisting for at least 6 weeks with
a clinical onset before 16 years of age. The disease spec-
trum spans from self-limited monoarthritis to ongoing
multiple joints destruction, and may involve severe
systemic manifestations or sight-threatening uveitis. In
order to provide a better quality on medical treatment and
follow-up, updated knowledge of the epidemiology, clinical
features, and course of JIA is essential. In the last decade,
our study group proposed the clinical features of juvenile
rheumatoid arthritis based on the American College of
Rheumatology system.1 To find a more homogenous disease
classification suitable for aetiopathogenetic studies, the
International League of Associations for Rheumatology
(ILAR) developed a new set of classification criteria for
childhood-onset idiopathic inflammatory arthritis and
called it JIA. The system was revised several times to
improve its usefulness. First proposed in 1994 (Santiago
criteria),2 the classification system was twice revised: in
1997 (Durban)3 and in 2001 (Edmonton).4 The distribution of
JIA categories in the Chinese population according to the
ILAR system, however, is lacking.
In view of this, our aim was to describe a cohort of
Chinese patients with JIA using the latest revision of ILAR
classification criteria. We also intended to emphasize on
the clinical manifestations, disease, and treatment course
of JIA in a community-based setting.
Patients and methods
The study was carried out at the pediatric rheumatologic
clinic of the Chang Gung Memorial Hospital (CGMH),
Kweishan (Taoyuan county, Northern Taiwan), which runs
an outpatient community referral clinic for the catchment
areas. Every week, 10e30 children with rheumatic diseases
are examined in the clinic. Although there are several
pediatric outpatient and inpatient facilities, the primary
health care, orthopedic, pediatric, and rheumatology
specialists in the catchment areas tend to refer children
with chronic joint pain to the CGMH. The prevalence of JIA
in Taiwan in 1999 was 3.8 per 100,000 inhabitants, as
previously reported by our study group.5
Patients
During the period 1995e2010, 292 children were suspected
of having chronic joint pain [diagnoses other than JIA were
nonspecific arthralgia (14), other connective tissue disor-
ders (17), and rheumatic fever (3)]. Beginning in January2002, we began to classify patients according to the ILAR
classification system and followed them in a longitudinal
observational cohort. From August to December 2011, we
carried out a final cross-sectional analysis. Several children
with loss of follow-up were recalled along with their
guardians for the final study visit. If they were unavailable,
they were contacted by telephone call. The minimal
requirement to stay included in the follow-up study cohort
was two registered visits, and all participants had been
followed for at least 18 months. Thirty-six children who had
incomplete clinical records and could not be interviewed
were excluded. We found that 195 children satisfied the
current ILAR classification criteria for JIA.
Detailed clinical profiles during the first year of illness
and investigation results were retrospectively reviewed and
collected in standard case record forms. JIA categories
were determined based on all available information regis-
tered at each visit during the study period, and for the
majority of children this was determined separately by two
of the authors (J.-L.H. and C.-C.S.). A few discrepancies
were settled by discussion. Disease onset was defined as
the date when the child, according to anamnestic infor-
mation, fulfilled the criteria of active arthritis or onset of
systemic features, not necessarily confirmed by a doctor.
Joints involvement was defined as joint swelling or limita-
tion in the range of joint movement with joint pain or
tenderness, which persists for at least 6 weeks. Uveitis was
diagnosed by an ophthalmologist. Remission status was
determined according to the preliminary criteria published
by Wallace et al.6 Occurrence of relapse was registered
if there is a presence of remission off medication for more
than 1 year, followed by new periods of activity. Human
leukocyte antigen (HLA)-B27 antigen (by micro-
lymphocytotoxicity assay or direct immunocytometry) was
analyzed at onset. Antinuclear antibodies (ANA; by indirect
immunofluorescence assay) and rheumatoid factor (RF; by
nephelometry) were analyzed twice, at least 3 months
apart. RF values 40 IU/mL or titers of ANA 1:40 were
classified as positive. The study was approved by the
Institutional Review Board of CGMH. All patients were
informed about our research.Statistical analyses
Descriptive statistics were shown as the median [inter-
quartile range (iqr)] for continuous variables and as
percentages for categorical variables. Categorical variables
were analyzed with Fisher’s exact test and Chi-square test
when appropriate. A p value <0.05 was considered signifi-
cant. Statistical analyses were performed using the SPSS
software package for Windows (version 17.0; SPSS, Chicago,
IL, USA).
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Characteristics of patients
Of the 195 included children classified as having JIA, 148
(75.9%) had a follow-up 5 years or more after the date of
diagnosis (median 8.7 years, iqr 6.0e12.5). Of the final
registrations, 150 (77.0%) were clinic visits and 45 were
telephone interviews. Telephone interviews were mainly
performed for participants when clinical follow-up had
been transferred from the pediatric rheumatologist either
to primary health care due to remission or to adult care
because of age.
The distribution of ILAR categories is shown in Fig. 1.
Enthesitis-related arthritis (ERA) was the single largest
category (37.4%), followed by oligoarthritis (23.1%) and
systemic arthritis (19.0%). Table 1 shows the clinical
features related to the ILAR classification system at the
final study visit. Of the 45 children with oligoarticular
onset, 13 (28.9%) had an extended course after the first 6
months of disease. Another two children had changed JIA
categories from oligoarthritis to ERA due to sacroiliac joint
involvement. Boys outnumbered girls at a ratio of 1.21:1.
Between the onset of disease and the diagnosis of arthritis
by a doctor, there was a median time interval of 120 days
(iqr 44e365). The median age at onset of this series was 9.5
years (iqr 6.3e12.0).
A total of 10 children (5.1%) were positive for RF, of
whom nine had seropositive polyarthritis and one had
undifferentiated arthritis. Positivity of HLA-B27 and ANA
titer were found in 62 (32.3%) and 65 (33.3%) cases,Figure 1. Distribution (%) of categories in 195 Taiwanese
children with JIA as per the ILAR classification system
(Edmonton, 2001). ERA Z enthesitis-related arthritis;
ILARZ International League of Associations for Rheumatology;
oJIA-E Z oligoarticular JIA; oJIA-P Z oligoarticular JIA,
persistent, extended; pJIA-SNZ polyarticular JIA, rheumatoid
factor negative; pJIA-SP Z polyarticular JIA, rheumatoid
factor positive; PsA Z psoriatic arthritis; sJIA Z systemic JIA;
UnA Z undifferentiated arthritis.respectively. ANA were positive in 58% at a dilution of 1:40,
in 22% at 1:80, in 11% at 1:160 and in 9% at 1:640. HLA-B27
and ANA were most common in the ERA category (95.2% and
30.8%, respectively). Uveitis developed in 13 (6.7%) of the
children with JIA, and 83% of these were diagnosed within
the first 4 years after onset of disease (data not shown).
The knee (59.5%) was the most frequently involved joint,
followed by ankle (42.1%) and wrist (34.4%).
Five children were classified as undifferentiated JIA
because they fulfilled the criteria in no category or in two
or more categories in the ILAR system. Table 2 provides an
overview of this subgroup. Three girls underwent an oli-
goarticular course with tested positivity for RF. One girl
with an otherwise typical manifestation of systemic
arthritis had a history of psoriasis. Another boy, who tested
positive for HLA-B27, developed systemic arthritis.
Medications
Table 3 summarizes the drug use in the observational
cohort. Intra-articular corticosteroid injections were per-
formed in 26.7% of the patients during the course of their
disease. Disease-modifying anti-rheumatic drugs were used
in 73.3% of the patients during the study period and in 32.3%
of the patients at the final study visit. Oral methotrexate
was the most common drug received, followed by azathi-
oprine and sulfasalazine. Biologic agents, mostly eta-
nercept, were used in 12.8% of patients during the study
period. One patient shifted to adalimumab after developing
etanercept-related uveitis. Another patient used rituximab
to treat the systemic arthritis.
Disease activity course
A continuously active disease course with no remissions off
medication during the observational period was seen in
33.3% of children (Table 4). There were also 6.7% of
patients experiencing a relapsing disease course with
remissions off medication for 1 year or more, followed by
new periods of disease activity. Forty percent of patients
had an active disease at the last follow-up. A significantly
higher rate of active disease was found in individuals with
ERA and RF-positive polyarthritis compared with the rest of
the cohort (p < 0.001). ANA was not associated with any
particular outcome pattern with regard to remission.
However, HLA-B27-positive patients experienced a contin-
uously active or relapsing disease compared with HLA-B27-
negative patients (p Z 0.002).
Discussion
In this study, 97% of Chinese children with chronic idio-
pathic inflammatory arthritis were classified into discrete
JIA categories using the latest revised ILAR classification
system (Edmonton, 2001). This success was in line with
what had been achieved earlier (87e95%) by investigators
in other regions or countries.7e10 With enrollment of a large
number of children with JIA in a community setting, this is
probably the first report of a systematic evaluation of the
current ILAR system in Taiwan. The results were similar
with those obtained in India and Turkey.7,8 However,
Table 1 Clinical features related to disease categories in children with JIA
Featuresa Systemic
arthritis
Oligoarthritis,
persistent
Oligoarthritis,
extended
Polyarthritis,
RF negative
Polyarthritis,
RF positive
Psoriatic
arthritis
Enthesitis-related
arthritis
Undifferentiated All
n Z 37 n Z 32 n Z 13 n Z 23 n Z 9 n Z 3 n Z 73 n Z 5 n Z 195
Disease onset,
yrb
6.7 (4.7e10.8) 6.3 (4.0e10.1) 8.0 (3.3e11.7) 9.4 (3.8e12.0) 10.1 (9.2e14.1) 9.4 (6.2e0.8) 10.8 (8.9e12.3) 10.2 (8.7e15.1) 9.5 (6.3e12.0)
Disease
duration, yr
8.7 (6.0e11.6) 10.6 (8.0e11.9) 10.8 (6.4e11.3) 9.5 (7.1e12.9) 7.2 (4.8e13.8) 11.0 (8.2e13.2) 7.6 (4.6e12.7) 10.1 (8.1e11.1) 8.7 (6.0e12.5)
Female 24 (64.9) 17 (53.1) 7 (53.8) 15 (65.2) 9 (100) 1 (33.3) 11 (15.1) 4 (80.0) 88 (45.1)
RF positive 0 (0) 0 (0) 0 (0) 0 (0) 9 (100) 0 (0) 0 (0) 1 (20.0) 11 (5.6)
ANA positive 10 (27) 15 (46.9) 2 (15.4) 8 (34.8) 7 (77.8) 12 (66.7) 20 (27.4) 1 (20.0) 65 (33.3)
HLA-B27 positive 0 (0) 1 (3.1) 0 (0) 0 (0) 1 (11.1) 1 (33.3) 60 (82.2) 0 (0) 63 (32.3)
CRP, mg/l 103 (78.1e150.8) 9 (3.3e12.9) 6 (4.4e16.6) 11.8 (4.9e22.1) 13.3 (4.3e26.6) 7.3 (3.1e11.8) 10.1 (4.9e18.5) 8.5 (4.1e13) 12 (5.2e32.7)
Hip 5 (13.5) 2 (6.3) 1 (7.7) 2 (8.7) 1 (11.1) 0 (0) 31 (42.5) 1 (20.0) 43 (2.1)
Knee 23 (62.2) 22 (68.8) 9 (69.2) 15 (65.2) 7 (77.8) 1 (33.3) 38 (52.1) 1 (20.0) 116 (59.5)
Ankle 17 (45.9) 7 (21.9) 9 (69.2) 12 (52.2) 5 (55.6) 2 (66.7) 28 (38.4) 2 (40.0) 82 (42.1)
Foot small joints 4 (10.8) 0 (0) 3 (23.1) 6 (26.1) 2 (22.2) 2 (66.7) 12 (16.4) 0 (0) 29 (14.9)
Shoulder 5 (13.5) 1 (3.1) 1 (7.7) 1 (7.7) 4 (44.4) 0 (0) 10 (13.7) 0 (0) 22 (11.3)
Elbow 10 (27.0) 4 (12.5) 6 (46.2) 11 (47.8) 4 (44.4) 0 (0) 5 (6.8) 1 (20.0) 41 (21.0)
Wrist 15 (40.5) 7 (21.9) 7 (53.8) 16 (69.6) 7 (77.8) 1 (33.3) 12 (16.4) 2 (40.0) 67 (34.4)
Hand small joints 15 (40.5) 1 (3.1) 3 (23.1) 13 (56.5) 7 (77.8) 1 (33.3) 13 (17.8) 1 (20.0) 54 (27.7)
SI joints/L-spine 1 (2.7) 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3) 35 (47.9) 0 (0) 37 (19.0)
Uveitis 3 (8.1) 3 (9.4) 1 (7.7) 0 (0) 0 (0) 0 (0) 7 (9.6) 0 (0) 13 (6.7)
a CRP was the initial value at diagnosis. Hip, knee, ankle, foot small joints, shoulder, wrist, hand small joints, SI joints/L-spine and uveitis were the joints involved during the study
period.
b Values are numbers (percentage of total no.) when indicated, other values are the medians (interquartile ranges).
JIA Z juvenile idiopathic arthritis; RF Z rheumatoid factors; ANA Z antinuclear antibodies; HLA-B27 Z human leukocyte antigen e B27; CRPZ C-reactive protein; SI Z sacroiliac;
L Z lumbar.
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Table 3 Drug treatment in children with JIA in the cohort
study
During the
study peroid
At the final
study visit
n Z 195 n Z 195
NSAID 190 (97.4) 99 (50.8)
Corticosteroid intra-articular 52 (26.7) e
Methotrexate 129 (66.1) 44 (22.6)
Azathioprine 44 (22.6) 17 (8.7)
Sulfasalazine 46 (23.6) 15 (7.7)
Cyclosporine 17 (8.7) 4 (2.1)
Biologic agentsa 25 (12.8) 20 (10.6)
Other medicationsb 10 (5.1) 2 (1.0)
DMARDc 143 (73.3) 63 (32.3)
No regular medication 5 (2.6) 88 (45.1)
a Biologic agents included etanercept, 1 adalimumab during
the study period (1 at the final study visit) and 1 rituximab (0).
b Other medications included 8 cyclophosphamide pulse
therapy (0), 1 hydroxychloroquine (1) and 1 mycophenolate
mofetil (1).
c DMARD Z methotrexate, azathioprine, sulfasalazine,
cyclosporine, biologic agents and other medications.
JIA Z juvenile idiopathic arthritis; NSAID Z non-steroidal anti-
inflammatory drug; DMARD Z disease-modifying antirheumatic
drug.
Table 2 Reasons for classifying 5 patients as undifferen-
tiated arthritis according to the ILAR system
N Sex Possible category Cause of exclusion/
Second category
1 F Systemic arthritis History of psoriasis
2 F Oligoarthritis, persistent RF positive
3 F Oligoarthritis, persistent RF positive
4 F Oligoarthritis, extended RF positive
5 M Systemic arthritis HLA-B27 positive
F Z female; M Z male; RF Z rheumatoid factors; HLA-B27 Z
human leukocyte antigen e B27.
Table 4 Remission status of children with JIA in the cohort stu
No. Active
disease
Remission on
medication
Rem
me
No. (%)a No. (%)a No.
Systemic 37 12 (32.4) 5 (13.5) 20 (5
Oligoarthritis, persistent 32 5 (15.6) 6 (18.8) 21 (6
Oligoarthritis, extended 13 5 (38.5) 3 (23.1) 5 (3
Polyarthritis, RF negative 23 9 (39.1) 3 (13.0) 11 (4
Polyarthritis, RF positive 9 5 (55.6) 3 (33.3) 1 (1
Psoriatic arthritis 3 0 (0) 1 (33.3) 2 (6
Enthesitis-related arthritis 73 41 (56.2) 8 (11.0) 24 (3
Undifferentiated 5 1 (20.0) 0 (0) 4 (8
All 195 78 (40.0) 29 (14.9) 88 (4
a Active disease, remission on medication and remission off medica
b Continuously active Z no periods of remission off medication dur
c Relapse everZ presence of remission off medication more than 1
d 95% interval Z 1.226e2.373, p Z 0.002.
JIA Z juvenile idiopathic arthritis; RF Z rheumatoid factors; RR Z r
292 C.-C. Shen et al.compared with previous reports in Western countries, the
cohort in Taiwan showed a quite different phenotypic
spectrum of JIA. ERA (prevalence, 37% in our study vs. 7%e
13% in Western countries9e15) was the most common JIA
category in Chinese children. In our study, because ERA
usually has its onset in late childhood or adolescence, the
age of onset of illness appeared comparatively higher with
a peak distributed over the pubertal stage. Similarly, this
reason may partly explain why boys outnumber girls in the
prevalence of JIA.
The knee, ankle, and wrist were the most frequently
involved joints in this series, whereas the small joints of the
hands and feet were affected mostly in patients with the
polyarthritis and ERA. The reported frequency of ocular
involvement varies worldwide: 10% in the United States,
12% in Germany, and 20% in the Nordic countries.9,15,16 The
relative infrequent prevalence in our study was in line with
rates obtained in other Asian countries (India, Korea, and
Japan).7,17,18
The current cohort study heightens the concept of JIA as
a chronic disease,19,20 showing that a substantial number of
children with JIA experience continuously ongoing disease
activity or a relapsing course, which extends into adult-
hood. Similar results were shown using the newly developed
remission criteria in retrospective studies for select cate-
gories of JIA by Wallace et al.6
The use of biologic agents in pediatric rheumatology
represents the beginning of a new era in medical treatment
of JIA.21 The major goal of modern treatment in JIA is
switched from control of disease to remission of disease
with or without medication.22,23 Indications and approvals
have been widened as efficacy and safety data on biologic
agents in children have emerged.24,25 Because etanercept
was introduced at about the same time our study started,
the use of biologic medications in 12.8% of our cohort
during disease course reflects the steadily increasing use
during the past decade and might have been higher under
Taiwan’s National Health Insurance program. In addition
to the biologic agents, non-steroidal anti-inflammatory
drugs remain the mainstay of medical treatment for JIA,dy
ission off
dication
Continuously
active
Relapse
ever
ANA(%) HLA-B27(%)
(%)a No. (%)b No. (%)c RR for continuously
active or relapse ever
4.1) 10 (27.0) 2 (5.4) 0.54 e
5.6) 4 (12.5) 1 (3.1) e 7.75
8.5) 2 (15.4) 3 (23.1) e e
7.8) 9 (39.1) 0 (0) 1.5 e
1.1) 5 (55.6) 0 (0) e e
6.7) 0 (0) 0 (0) e e
2.9) 35 (47.9) 6 (8.2) 0.97 1.05
.0) 0 (0) 1 (20.0) e e
5.1) 65 (33.3) 13 (6.7) 1.12 1.71d
tion means the status at the final study visit.
ing the study period.
year, followed by new periods of activity during the study period.
elative risk.
Clinical features of JIA in Taiwan 293followed by intra-articular corticosteroid injection and
disease-modifying anti-rheumatic drugs. The timing and
choice of these drugs differed from the report described by
Cron et al.26 As a whole, apart from non-steroidal anti-
inflammatory drugs and steroids, methotrexate was the
most common treatment; sulfasalazine, azathioprine, and
cyclosporine were reserved for children who did not
respond to a less aggressive therapy. Nevertheless, in
a review of literature, sulfasalazine and azathioprine were
effective and well-tolerated in Chinese children with
JIA.27,28
The 33% positive rate of ANA conforms with the 30e50%
found in previous Caucasian studies.29,30 It has been re-
ported that ANA-positive patients are more likely to have
uveitis.31 The presence of ANA has recently also been sug-
gested as an important prognostic descriptor to be incor-
porated in the revised ILAR classification.32 However, we
found that ANA positivity was not correlated with remission
status or comorbid uveitis. This is probably because the
majority (58%) of our ANA-positive patients showed a low
ANA titer of 1:40, and the prevalence of uveitis was low.
A high proportion (32.3%) of HLA-B27 positivity was
shown in the present study. Similar observations have been
reported in studies conducted on non-European pop-
ulations.7,8 Onset of arthritis after 6 years in a boy with
HLA-B27 is a strong indicator for ERA in the current ILAR
system and an exclusion for other categories. Intriguingly,
we found that our patients with HLA-B27 positivity tend to
have a continuously active or relapsing course. Recently,
indication of poor outcome in JIA according to HLA-B27 has
emerged. Hsu et al33 linked HLA-B27 to failure of first
remission in children with newly diagnosed JIA. Pruunsild
et al34 also found that HLA-B27-positive patients had
a longer period of elevated blood inflammation markers
compared with HLA-B27-negative patients.
The limitations of this study are its cross-sectional
nature and hospital-based design. However, this is the
first study to describe the clinical profile of JIA according to
the latest ILAR system in a Chinese cohort. The present
results also provided a good starting point in understanding
the epidemiology of this serious disease in the Chinese
population.
In conclusion, the major characteristics of JIA shown
in this study included the predominance of ERA, a higher
prevalence in boys, and lower prevalence of uveitis.
Approximately one-half of the patients experienced
a continuously active or relapsing course. The presence of
HLA-B27 might have a predictive value for the remission
status. These figures probably reflect the indigenous clin-
icaleimmunogenetic character of the Chinese population.
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